Bullfrog AI Holdings Inc BFRG

$0.49 +0.00 (0.12%)

Valuation

Market cap
9,145,000
Revenue TTM
$120,000
Net income TTM
$-6,500,000
PE ratio
0.00
Forward PE
—
Profit margin
-5,416.67%
Debt to equity
0.01

Trading

Volume
107,400
Avg volume
6,836,430
Day's range
$0.48 – $0.51
Shares out
18,542,000
Stochastic %K
13%
Beta
-2.73
Analysts
Hold
Price target
—

Price

Company profile

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a n...

Show more

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Industry
Health Information Services
Sector
Healthcare
Phone
240 658 6710
Website
https://www.bullfrogai.com
Address
325 Ellington Boulevard, Unit 317, Gaithersburg, United States

Latest news

Stocktwits

rayzer202 Oct 24, 3:04 AM
$BFRG director of PR job filled along with other data scientist role, now HR job posted, good sign they’re filling positions and ramping up, they must see a lot more work in the near term
0 replies
Newmoves Oct 23, 8:19 PM
$BFRG on the last conference Vin just attended he sounded the absolute most confident than he ever has. Just one decent deal here will make this company profitable and compliant. They have built a nice company here just strike a real deal here now! Sounds like at least one or 2 deals are possible in Q4 according to CEO. Could make an announcement soon enough. Slowing adding to this rock bottom price. Don’t forget management just bought around these levels
0 replies
WeTheMarket Oct 23, 1:01 PM
$BFRG $DJT $TSLA $SPCX $PLTR Worth sharing. Feel free to pass along. Key quote: "Remember my name. Perhaps I won’t be able to speak anymore. But as long as I am alive, I have one hope: to see a free and prosperous Iran before the noose ends my life." We can only hope, for Najmeh Amini, and for all of us, and not just from a market perspective. https://iranhumanrights.org/2026/10/iranian-student-sentenced-to-death-over-social-media-post/
0 replies
WeTheMarket Oct 23, 9:50 AM
$BFRG Link to latest Investor Presentation slides, dated October 20, 2026. https://d1io3yog0oux5.cloudfront.net/_460ce57b8f432a121a9e1199265c375f/bullfrogai/db/2639/25122/pdf/BFRG+Corporate+Presentation_October+2026.pdf
0 replies
Pufferfish1026 Oct 22, 10:36 PM
$BFRG Looks like the replay of Bullfrog AI's 20th Annual LD Micro Main Event presentation is available at https://ldmicroevents.com/ On the main page click "Watch Live" then scroll down and click "Replay Track 3". I believe Vin starts presenting around 3:49:20.
0 replies
JuanValdex Oct 22, 12:55 PM
$BFRG Price Target $3.00 Q1 ignore tax loss sell/rebuys. 10 targets in MDD study... have to believe at least 2 will hit.
0 replies
WeTheMarket Oct 20, 8:41 PM
$BFRG Key quotes: - We're not looking to develop drugs. We're all about revenue. I think optimistic about this fourth quarter. I think we're going to have multiple opportunities. And we're going to continue growing from there. So really excited about the direction we're headed. The other thing is, we want to take our tech stack and make it an enterprise solution. - So the first one took one year. From the first conversation to closing the deal. And I think that's sort of the generally accepted sales cycle. Nine to 18 months for Big Pharma. We already have others in our pipeline. I think there's an opportunity to actually close one or two of those this quarter. - The deals that we're really going after, we'll call them bio bucks deals. So if you ever read about the billion-dollar multi-billion-dollar deal with an AI and a Big Pharma, those are called bio bucks. That means maybe there's 50 million upfront. There's milestone payments. There's royalties. So you have cash flow stream . . .
1 replies
WeTheMarket Oct 20, 8:24 PM
$BFRG Following are insights from Microsoft Copilot. The most meaningful statement in the entire presentation was not the technology discussion. It was the repeated assertion that the pharma partner wants to expand the relationship and that BullFrog may be able to move from pilot-style engagements to larger standard pharma contracts. For BFRG shareholders, the next 6-12 months likely hinge on three developments: 1. Identification or eventual disclosure of the Top-5 pharma partner. 2. Expansion of that relationship into additional programs. 3. Conversion of the stated 36-opportunity pipeline into signed contracts. If those occur, the story changes from "interesting AI technology" to "commercial adoption by global pharma," which is where valuations in this sector typically begin to re-rate. Overall, I would characterize this presentation as commercially encouraging and execution-focused, with the strongest signal being management's confidence around follow-on pharma business.
0 replies